51 related articles for article (PubMed ID: 33225872)
41. Synthetic Cannabinoids.
Mills B; Yepes A; Nugent K
Am J Med Sci; 2015 Jul; 350(1):59-62. PubMed ID: 26132518
[TBL] [Abstract][Full Text] [Related]
42. Novel psychoactive substances: the pharmacology of stimulants and hallucinogens.
Schifano F; Papanti GD; Orsolini L; Corkery JM
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):943-54. PubMed ID: 26985969
[TBL] [Abstract][Full Text] [Related]
43. Fifteen-minute consultation: Recognition and management of the child or young person who has ingested a novel psychoactive substance.
Tubman L; Mullen N; Tracy DK
Arch Dis Child Educ Pract Ed; 2020 Dec; 105(6):336-341. PubMed ID: 32366379
[TBL] [Abstract][Full Text] [Related]
44. Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists.
Wouters E; Walraed J; Banister SD; Stove CP
Biochem Pharmacol; 2019 Nov; 169():113623. PubMed ID: 31472128
[TBL] [Abstract][Full Text] [Related]
45. Cannabinoids in health and disease.
Kogan NM; Mechoulam R
Dialogues Clin Neurosci; 2007; 9(4):413-30. PubMed ID: 18286801
[TBL] [Abstract][Full Text] [Related]
46. The Synthetic Cannabinoids Phenomenon.
Karila L; Benyamina A; Blecha L; Cottencin O; Billieux J
Curr Pharm Des; 2016; 22(42):6420-6425. PubMed ID: 27655416
[TBL] [Abstract][Full Text] [Related]
47. Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation.
Tebo C; Mazer-Amirshahi M; Wax P; Campleman S; Boyer E; Brent J; Sheth A; Daniuaityte R; Carlson R
J Psychoactive Drugs; 2021; 53(3):207-214. PubMed ID: 33225872
[TBL] [Abstract][Full Text] [Related]
48. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.
Banister SD; Connor M
Handb Exp Pharmacol; 2018; 252():165-190. PubMed ID: 29980914
[TBL] [Abstract][Full Text] [Related]
49. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.
Chung EY; Cha HJ; Min HK; Yun J
Arch Pharm Res; 2021 Apr; 44(4):402-413. PubMed ID: 33811300
[TBL] [Abstract][Full Text] [Related]
50. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
van Amsterdam J; Brunt T; van den Brink W
J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
[TBL] [Abstract][Full Text] [Related]
51. Fourth Generation of Synthetic Cannabinoid Receptor Agonists: A Review on the Latest Insights.
Malaca S; Busardò FP; Nittari G; Sirignano A; Ricci G
Curr Pharm Des; 2022; 28(32):2603-2617. PubMed ID: 34781870
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
